[1] Sharma A, Keshava SN, Eapen A, et al. An update on the management of Budd-Chiari syndrome. Dig Dis Sci, 2021,66:1780-1790.
[2] Coilly A, Potier P, Broué P, et al. Budd-Chiari syndrome. Clin Res Hepatol Gastroenterol, 2020,44:420-425.
[3] Van Wettere M, Bruno O, Rautou PE, et al. Diagnosis of Budd-Chiari syndrome. Abdom Radiol (NY), 2018,43:1896-1907.
[4] Qi X, Guo X, Fan D. Difference in Budd-Chiari syndrome between the West and China. Hepatology, 2015,62:656.
[5] Ki M, Choi HY, Kim KA, et al. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int, 2016,36:1067-1073.
[6] Zhang W, Qi X, Zhang X, et al. Budd-Chiari syndrome in china: a systematic analysis of epidemiological features based on the chinese literature survey. Gastroenterol Res Pract, 2015,2015:738548.
[7] Groeneveld D, Cline-Fedewa H, Baker KS, et al. Von willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice. J Hepatol, 2020,72:146-155.
[8] Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood, 2012,120:4921-4928.
[9] Hernández-Gea V, De Gottardi A, Leebeek FWG, et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. J Hepatol, 2019,71:175-199.
[10] Alukal JJ, Zhang T, Thuluvath PJ. A nationwide analysis of budd-chiari syndrome in the united states. J Clin Exp Hepatol, 2021,11:181-187.
[11] 王珺,孙桂香,陆召军,等. 布加氏综合征基本分布情况调查与分析. 中华疾病控制杂志,2010,14:675-677.
[12] Sonavane AD, Amarapurkar DN, Rathod KR, et al. Long term survival of patients undergoing TIPS in Budd-Chiari syndrome. J Clin Exp Hepatol, 2019,9:56-61.
[13] He FL, Wang L, Zhao HW, et al. Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome. World J Gastroenterol, 2015,21:2413-2418. |
